Author

J. Yoshino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Physiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:metabolism & bioenergetics· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

S. Klein· 4 shared B. J. Renquist· 2 shared C. E. Geisler· 2 shared K. E. Miller· 2 shared S. Ghimire· 2 shared A. J. Lutkewitte· 1 shared A. LaPoint· 1 shared A. R. Cox· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPhysiology

S. Klein

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Adipocyte lipin 1 is positively associated with metabolic health in humans and regulates systemic metabolism in mice.

A. LaPoint, J. M. Singer, D. Ferguson, T. M. Shew, K. RenKemeyer, H. Palacios, R. Field, M. Shankaran, G. I. Smith, J. Yoshino, M. He, G. J. Patti, M. Hellerstein, S. Klein, J. R. Brestoff, , A. J. Lutkewitte

The paper shows that lower adipose lipin 1 in humans correlates with metabolic issues, and mice lacking adipocyte lipin 1 develop metabolic disorders.

bioRxiv · Feb 1, 2023 · PreprintPhysiology

Accumulation of auranofin in white adipose tissues lowers leptin levels and exerts anti-diabetic effects

A. R. Cox, P. M. Masschelin, P. Saha, J. B. Felix, R. Sharp, Z. Lian, Y. Xia, N. Chernis, D. A. Bader, K. H. Kim, X. Li, J. Yoshino, X. Li, Z. Sun, H. Wu, , S. M. Hartig

The paper identifies auranofin as a drug that lowers leptin levels in white adipose tissue and improves insulin sensitivity in obese mice, with anti-diabetic effects.

bioRxiv · Sep 11, 2021 · PreprintPhysiology

A Critical Role of Hepatic GABA in The Metabolic Dysfunction and Hyperphagia of Obesity

C. E. Geisler, S. Ghimire, S. M. Bruggink, K. E. Miller, S. N. Weninger, J. M. Kronenfeld, J. Yoshino, S. Klein, F. A. Duca, B. J. Renquist

This study shows that inhibiting hepatic GABA production in obese mice reduces hyperinsulinemia, improves glucose tolerance, and decreases food intake, suggesting a role for hepatic GABA in obesity-related metabolic dysfunction.

bioRxiv · Apr 2, 2020Physiology

Hepatocyte Membrane Potential Regulates Serum Insulin and Insulin Sensitivity by Altering Hepatic GABA Release

C. E. Geisler, S. Ghimire, C. Hepler, K. E. Miller, M. R. Higgins, J. Yoshino, S. Klein, B. J. Renquist

This study identifies GABA as a novel hepatokine dysregulated in obesity, showing that hepatic GABA release affects serum insulin and insulin sensitivity.

bioRxiv · Apr 2, 2020Physiology